Medical Device News Magazine is the leading resource for medical device M&A information. We provide coverage of all the latest deals, as well as insights and analyses from industry experts.
Our readers rely on us for the most up-to-date information on the medical device market. We are focused on delivering the most comprehensive news coverage possible. Whether you are a CEO, CFO, investor, or employee of a medical device company, MDNM is the source you can trust for all your merger and acquisition news.
“Respiratory care has been central to ZOLL’s business strategy for many years,” said Jon Rennert, CEO of ZOLL. “If the acquisition is successfully completed, adding Vyaire’s ventilators to ZOLL’s product portfolio will enhance our ability to serve a broader range of clinicians and patients.”
The acquisition is a strategic step towards the company’s ambition to offer solutions for every step of viral vector manufacturing. It also reinforces the company’s commitment to supporting customers in advancing cell and gene therapies from preclinical through commercial production. The Life Science business of Merck KGaA, Darmstadt, Germany acquired Mirus Bio from Gamma Biosciences, a life sciences platform established by global investment firm KKR.
BIOVECTRA and Agilent Technologies are fully integrated CDMOs with state-of-the-art facilities that follow current Good Manufacturing Practices (cGMP), a high standard for methods, facilities, and controls used in manufacturing, processing, and packaging of active pharmaceutical ingredients.
“As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio”, says Gabriel Baertschi, CEO, Grünenthal. “The acquisition of Valinor Pharma strengthens our footprint in the United States, the most important growth market for Grünenthal.”
Under the Asset Purchase Agreement, Meitheal Pharmaceuticals acquires North America rights to CONTEPO™, including any results of development and regulatory activities, and all intellectual property (IP) rights, technology, and know-how related to CONTEPO™. In exchange, Nabriva will receive payment upon closing and a royalty on net U.S. sales of CONTEPO™.
Zensar Technologies notes this strategic move strengthens Zensar’s Healthcare and Life Sciences (HLS) vertical and expands its pharma commercial and product launch expertise.